Jay S. Duker - Feb 9, 2022 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Operating Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Feb 9, 2022
Transactions value $
$0
Form type
4
Date filed
2/11/2022, 03:41 PM
Previous filing
Nov 3, 2021
Next filing
Jun 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +4.97K +87.79% $0.00 10.6K Feb 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Award $0 +21K $0.00 21K Feb 9, 2022 Common Stock 21K $0.00 Direct F1
transaction EYPT Restricted Stock Units Options Exercise $0 -4.97K -33.33% $0.00 9.93K Feb 9, 2022 Common Stock 4.97K $0.00 Direct F2
transaction EYPT Stock Option (Right to Buy) Award $0 +85K $0.00 85K Feb 9, 2022 Common Stock 85K $10.13 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units will vest in three ratable annual installments beginning February 9, 2023.
F2 The restricted stock units vest in three ratable annual installments beginning February 9, 2022.
F3 The option to purchase will vest and become exercisable as follows: 25% at February 9th, 2023 and the remainder ratably, on a monthly basis, over the remaining three years.